TransMedics Group Inc (NASDAQ:TMDX) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 1,490,000 shares, an increase of 11.2% from the December 15th total of 1,340,000 shares. Based on an average daily volume of 185,200 shares, the days-to-cover ratio is currently 8.0 days. Currently, 12.1% of the company’s stock are short sold.

In related news, Director David Weill acquired 10,000 shares of TransMedics Group stock in a transaction on Monday, November 11th. The shares were bought at an average price of $17.00 per share, for a total transaction of $170,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $170,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

A number of institutional investors have recently made changes to their positions in TMDX. NumerixS Investment Technologies Inc bought a new stake in TransMedics Group in the second quarter valued at about $43,000. JPMorgan Chase & Co. bought a new position in shares of TransMedics Group during the second quarter valued at approximately $50,000. Boston Partners bought a new position in shares of TransMedics Group during the third quarter valued at approximately $96,000. Tower Research Capital LLC TRC bought a new position in shares of TransMedics Group during the second quarter valued at approximately $190,000. Finally, Blackstone Group Inc bought a new position in shares of TransMedics Group during the second quarter valued at approximately $290,000. 67.59% of the stock is owned by hedge funds and other institutional investors.

Several research firms recently commented on TMDX. Zacks Investment Research upgraded TransMedics Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Cowen cut their price target on TransMedics Group from $40.00 to $28.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $33.00.

TransMedics Group stock traded up $0.55 during midday trading on Tuesday, hitting $19.61. The stock had a trading volume of 220 shares, compared to its average volume of 237,189. The company has a quick ratio of 6.61, a current ratio of 7.33 and a debt-to-equity ratio of 0.54. TransMedics Group has a 12 month low of $15.74 and a 12 month high of $31.54. The business has a fifty day moving average price of $18.72 and a 200 day moving average price of $21.18.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.39) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.08. The firm had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.67 million. On average, sell-side analysts forecast that TransMedics Group will post -2.02 earnings per share for the current fiscal year.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Featured Article: Bid-Ask Spread

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.